ARTICLE | Clinical News

Moventig naloxegol regulatory update

September 29, 2014 7:00 AM UTC

EMA's CHMP recommended approval of the MAA for Moventig naloxegol from AstraZeneca to treat opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxatives. Earlier this month, FDA approved naloxegol as Movantik to treat OIC in adults with chronic non-cancer pain. AZ plans to launch the product in the U.S. next half (see BioCentury, Sept. 22). ...